МODERN NON-INVASIVE METHODS FOR TREATING PEYRONIE'S DISEASE
Abstract
Summary: Peyronie's disease (PD) is a common disease in men that can lead to significant penile deformity and pain, erectile dysfunction, and mental health problems. So far, surgical correction with plaque removal offers the greatest likelihood of success during the stable phase of the disease. However, for men in the acute phase of PD or those with a milder deformity who choose to avoid surgery, conservative treatment methods are also available.
New innovative methods are extracorporeal shock wave therapy (ESWT) and ultrasound therapy. Intralesional therapy with IFN-α2b, verapamil, and Clostridium histolyticum (CCH) collagenase can significantly reduce penile deviation (PD), but these results may not be clinically significant in men with more severe disease. Iontophoresis (EMDA, electromotive drug administration) of verapamil and cortisone have shown reductions in PD and penile pain.Penile traction therapy offers clinically significant improvement in penile length and curvature. It requires daily therapy lasting several hours. Oral therapies with substances such as L-arginine, L-citrulline, vitamin E and phosphodiesterase inhibitors are most helpful as part of a combination regimen rather than as monotherapy. Regenerative therapies with stem cells and platelet-rich plasma, as well as intralesional therapy with botulinum toxin (Botox) have not yet been well clinically studied and their possible application is currently taking place within the framework of clinical research. The combination of various oral, topical, intralesional therapies, extracorporeal shock wave therapy, ultrasound and traction therapies together with clinical psychosexual therapy if needed could provide a more effective treatment, which in turn could prevent or reduce the need for definitive reconstructive penile surgery.
Materials and methods: For the purposes of the literature review, a systematic search was conducted for articles in German and English on non-invasive treatment methods for Peyronie's disease. The articles were selected according to their relevance to the given topic. The main findings were summarized and presented in tabular form.
References
Devine CJ, JR., Somers KD, Jordan GH, Schlossberg SM. Proposal: Trauma as the Cause of the Peyronie's Lesion. The Journal of urology 1997;157:285–90.
Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-Based Management Guidelines on Peyronie's Disease. The journal of sexual medicine 2016;13:905–23.
Chung E, Young L de, Brock GB. Rat as an animal model for Peyronie's disease research: a review of current methods and the peer-reviewed literature. International journal of impotence research 2011;23:235–41.
Gonzalez-Cadavid NF, Rajfer J. Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nature clinical practice. Urology 2005;2:291–97.
Chung E, Yafi FA. Pharmacotherapy in Peyronie’s disease: a state-of-the-art review on established contemporary and emerging drugs. Expert opinion on pharmacotherapy 2022:1–8.
Pryor JP, Ralph DJ. Clinical presentations of Peyronie's disease. International journal of impotence research 2002;14:414–17.
Mulhall JP, Schiff J, Guhring P. An Analysis of the Natural History of Peyronie’s Disease. The Journal of urology 2006;175:2115–18.
Kuja-Halkola R, Henningsohn L, D'Onofrio BM, Mills J, Adolfsson A, Larsson H, et al. Mental Disorders in Peyronie's Disease: A Swedish Cohort Study of 3.5 Million Men. The Journal of urology 2021;205:864–70.
Al-Thakafi S, Al-Hathal N. Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl. Androl. Urol. 2016;5:280–89.
Pavone C, D'Amato F, Dispensa N, Torretta F, Magno C. Smoking, diabetes, blood hypertension: possible etiologic role for Peyronie's disease? Analysis in 279 patients with a control group in Sicily. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2015;87:20–24.
Rhoden EL, Riedner CE, Fuchs SC, Fuchs S, Ribeiro EP, Halmenschlager G. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease. The journal of sexual medicine 2010;7:1529–37.
Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie's Disease: AUA Guideline. The Journal of urology 2015;194:745–53.
Tsambarlis P, Levine LA. Nonsurgical management of Peyronie's disease. Nature Reviews Urology 2019;16:172–86.
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction. European urology 2021;80:333–57.
Abu-Ghanem Y, Kitrey ND, Gruenwald I, Appel B, Vardi Y. Penile low-intensity shock wave therapy: a promising novel modality for erectile dysfunction. Korean Journal of Urology 2014;55:295–99.
Wang C-J, Wang F-S, Yang KD, Weng L-H, Hsu C-C, Huang C-S, et al. Shock wave therapy induces neovascularization at the tendon–bone junction. A study in rabbits. J. Orthop. Res. 2003;21:984–89.
Lin G, Reed-Maldonado AB, Wang B, Lee Y-C, Zhou J, Lu Z, et al. In Situ Activation of Penile Progenitor Cells With Low-Intensity Extracorporeal Shockwave Therapy. The journal of sexual medicine 2017;14:493–501.
Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. EAU guidelines on penile curvature. European urology 2012;62:543–52.
Berardinis E de, Busetto GM, Antonini G, Giovannone R, Gentile V. Extracorporeal shock wave therapy in the treatment of Peyronie's disease: long-term results. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2010;82:128–33.
Chung E. Peyronie's disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men. Korean Journal of Urology 2015;56:775–80.
Di Mauro M, Russo GI, Della Camera PA, Di Maida F, Cito G, Mondaini N, et al. Extracorporeal Shock Wave Therapy in Peyronie's Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study. The World Journal of Men's Health 2019;37:339–46.
Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. The journal of sexual medicine 2013;10:2815–21.
Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. International journal of andrology 2012;35:190–95.
Strebel RT, Suter S, Sautter T, Hauri D. Extracorporeal shockwave therapy for Peyronie's disease does not correct penile deformity. International journal of impotence research 2004;16:448–51.
Abdessater M, Akakpo W, Kanbar A, Parra J, Seisen T, Chartier-Kastler E, et al. Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience. Asian Journal of Andrology 2022;24:45–49.
Srirangam SJ, Manikandan R, Hussain J, Collins GN, O'Reilly PH. Long-term results of extracorporeal shockwave therapy for Peyronie's disease. Journal of endourology 2006;20:880–84.
Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial. BJU international 2010;106:1352–56.
Weinberger JM, Shahinyan GK, Yang SC, Shahinyan RH, Mills JN, Eleswarapu SV. Shock Wave Therapy for Erectile Dysfunction: Marketing and Practice Trends in Major Metropolitan Areas in the United States. Urology Practice 2022;9:212–19.
Speed CA. Therapeutic ultrasound in soft tissue lesions. Rheumatology (Oxford, England) 2001;40:1331–36.
Ultrasound: current concepts; 1991.
Peyronie's disease and the role of therapeutic ultrasound: A randomized controlled trial; 2020.
Li Z, Jin Z. Comparative effect and safety of verapamil in keloid and hypertrophic scar treatment: a meta-analysis. Therapeutics and clinical risk management 2016;12:1635–41.
Lee RC, Ping J. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. Journal of Surgical Research 1990;49:463–66.
Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. The Journal of cell biology 1984;98:1662–71.
Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU international 2002;89:895–900.
Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. The journal of sexual medicine 2012;9:288–95.
Dell'Atti L. Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease. Urology annals 2015;7:345–49.
Favilla V, Russo GI, Privitera S, Castelli T, Madonia M, La Vignera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study. Andrologia 2014;46:936–42.
Gontero P, Di Marco M, Giubilei G, Pisano F, Bonazzi A, Soria F, et al. UP-03.052 Combination of Andropenis® Penile Extender and Oral Therapy (Peironimev ®) Versus Intralesional Verpamil for Penile Curvature Due To Peyronie's Disease: Preliminary Results of a Randomized Phase II Trial. Urology 2011;78:S360.
Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. The Journal of urology 1997;158:1395–99.
Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007;69:950–54.
Rehman J, Benet A, Melman A. Use of Intralesional Verapamil to Dissolve Peyronie’s Disease Plaque: A Long-Term Single-Blind Study. Urology 1998;51:620–26.
Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007;69:1181–84.
Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. International urology and nephrology 2009;41:467–71.
Walton EL, Quinn TP, Mulloy E, Patil D, Mehta A. Cost of Intralesional Collagenase Clostridium Histiolyticum Therapy Versus Surgery for the Management of Peyronie's Disease: A Claims-Based Analysis (2009-2019). Sexual medicine 2022;10:100517.
Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scandinavian journal of urology and nephrology 1991;25:89–94.
Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJG. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. The journal of sexual medicine 2005;2:709–15.
Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon α-2b for Minimally Invasive Treatment for Peyronie’s Disease. The Journal of urology 2006;176:394–98.
Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJG. Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. The Journal of urology 2013;190:2194–99.
Stewart CA, Yafi FA, Knoedler M, Mandava SH, McCaslin IR, Sangkum P, et al. Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location. The Journal of urology 2015;194:1704–07.
Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology 2006;67:1038–42.
Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urological research 1982;10:135–40.
Gelbard MK, Lindner A, Kaufman JJ. The Use of Collagenase in the Treatment of Peyronie’s Disease. The Journal of urology 1985;134:280–83.
Chung E, Scott S, Wang J. A state-of-art review on collagenase Clostridium Histolyticum and Peyronie's disease: drug profile, clinical evidence and safety outcomes. Expert opinion on biological therapy 2020;20:559–64.
Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. The Journal of urology 2013;190:199–207.
Melgarejo-Segura MT, Funes-Padilla C, Morales-Martínez A, López-Carmona-Pintado F, Arrabal-Martín M. Safety and Efficacy Study of Collagenase Clostridium Histolyticum Applied With an Intensive Protocol in the Treatment of Peyronie's Disease. Sexual medicine 2021;9:100375.
Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJG. Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients With Peyronie's Disease. Urology 2017;100:125–30.
Fernández-Pascual E, González-García FJ, Angulo J, Cerezo E, Quintana LM, Turo J, et al. Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling. BJU international 2019;124:1055–62.
Amighi A, Mills SA, Eleswarapu SV, Regets KV, Mendhiratta N, Mills JN. A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease results in reduced procedural morbidity using a standardized hematoma classification rubric. World journal of urology 2020;38:293–98.
Litwiniuk M, Krejner A, Speyrer MS, Gauto AR, Grzela T. Hyaluronic Acid in Inflammation and Tissue Regeneration. Wounds : a compendium of clinical research and practice 2016;28:78–88.
Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease. International urology and nephrology 2015;47:1595–602.
Zucchi A, Costantini E, Cai T, Cavallini G, Liguori G, Favilla V, et al. Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study. Sexual medicine 2016;4:e83-8.
Favilla V, Russo GI, Zucchi A, Siracusa G, Privitera S, Cimino S, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. Andrology 2017;5:771–75.
Cocci A, Di Maida F, Cito G, Verrienti P, Laruccia N, Campi R, et al. Comparison of Intralesional Hyaluronic Acid vs. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study. The World Journal of Men's Health 2021;39:352–57.
Cai T, Tiscione D, Favilla V, Puglisi M, Palumbo F, Zucchi A, et al. Oral Administration and Intralesional Injection of Hyaluronic Acid Versus Intralesional Injection Alone in Peyronie's Disease: Results from a Phase III Study. The World Journal of Men's Health 2021;39:526–32.
Kos B, Vásquez JL, Miklavčič D, Hermann GGG, Gehl J. Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA). PeerJ 2016;4:e2309.
Hashemi S, Sahai A, Malde S. Applications of electromotive drug administration in urology. Urology annals 2020;12:301–08.
Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. The Journal of urology 2003;169:1775–78.
Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. The Journal of urology 2007;177:972–75.
Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. The Journal of urology 2004;171:1605–08.
Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease. Andrology 2013;1:129–32.
Jeengar MK, Rompicharla SVK, Shrivastava S, Chella N, Shastri NR, Naidu VGM, et al. Emu oil based nano-emulgel for topical delivery of curcumin. International journal of pharmaceutics 2016;506:222–36.
Twidwell J, Levine L. Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. International journal of impotence research 2016;28:41–45.
Chung E, Young L de, Solomon M, Brock GB. Peyronie's disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system. The journal of sexual medicine 2013;10:1259–67.
Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Disease models & mechanisms 2014;7:193–203.
Matrix Metalloproteases in Aberrant Fibrotic Tissue Remodeling. Proceedings of the American Thoracic Society.
El-Sakka AI, Salabas E, Dinçer M, Kadioglu A. The pathophysiology of Peyronie's disease. Arab Journal of Urology 2013;11:272–77.
Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. The journal of sexual medicine 2008;5:1468–73.
Martínez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L, et al. Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. The journal of sexual medicine 2014;11:506–15.
Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, et al. Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study. BJU international 2019;123:694–702.
Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T, et al. Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial. The Journal of urology 2019;202:599–610.
Wymer K, Kohler T, Trost L. Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie's Disease in an Era of Effective Clinical Treatment. The journal of sexual medicine 2019;16:1421–32.
Yuan J, Lin H, Li P, Zhang R, Luo A, Berardinelli F, et al. Molecular mechanisms of vacuum therapy in penile rehabilitation: a novel animal study. European urology 2010;58:773–80.
Lin H, Liu C, Wang R. Effect of Penile Traction and Vacuum Erectile Device for Peyronie's Disease in an Animal Model. The journal of sexual medicine 2017;14:1270–76.
Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU international 2010;106:1178–80.
Mortensen J, Skov-Jeppesen SM, Ladegaard PBJ, Lund L. A Randomized, Single-Blinded Clinical Trial Evaluating the Effect of Extracorporeal Shockwave Treatment (ESWT) as Add-On Therapy to Vacuum Erectile Device on Peyronie's Disease. Research and reports in urology 2021;13:715–22.
Farrell MR, Ziegelmann MJ, Levine LA. Minimally invasive therapies for Peyronie's disease: the current state of the art. Transl. Androl. Urol. 2020;9:S269-S283.
Burri A, Porst H. The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie's Disease (PD). International journal of impotence research 2018;30:171–78.
Levine LA, Latchamsetty KC. Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate. International journal of impotence research 2002;14:478–82.
Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nature Reviews Urology 2010;7:215–21.
Goldstein I, Burnett AL, Rosen RC, Park PW, Stecher VJ. The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. Sexual medicine reviews 2019;7:115–28.
Valente EGA, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric oxide : biology and chemistry 2003;9:229–44.
Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU international 2006;97:625–33.
Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. The journal of sexual medicine 2011;8:1472–77.
Cocci A, Cito G, Urzì D, Minervini A, Di Maida F, Sessa F, et al. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis. The journal of sexual medicine 2018;15:1472–77.
Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nature clinical practice. Urology 2006;3:111-5; quiz 116.
Smith JF, Shindel AW, Huang Y-C, Clavijo RI, Flechner L, Breyer BN, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian Journal of Andrology 2011;13:322–25.
Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline. Global journal of health science 2014;6:23–30.
Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study. Research and reports in urology 2016;8:1–10.
Barassi A, Corsi Romanelli MM, Pezzilli R, Damele CAL, Vaccalluzzo L, Goi G, et al. Levels of l-arginine and l-citrulline in patients with erectile dysfunction of different etiology. Andrology 2017;5:256–61.
Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Inflammation & allergy drug targets 2012;11:48–57.
Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. Dietary arginine uptake by the splanchnic region in adult humans. The American journal of physiology 1993;265:E532-9.
Grimble GK. Adverse gastrointestinal effects of arginine and related amino acids. The Journal of nutrition 2007;137:1693S-1701S.
van de Poll MCG, Siroen MPC, van Leeuwen PAM, Soeters PB, Melis GC, Boelens PG, et al. Interorgan amino acid exchange in humans: consequences for arginine and citrulline metabolism. The American journal of clinical nutrition 2007;85:167–72.
Szymańska R, Nowicka B, Kruk J. Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition. Mini reviews in medicinal chemistry 2017;17:1039–52.
Sikka SC, Hellstrom WJG. Role of oxidative stress and antioxidants in Peyronie's disease. International journal of impotence research 2002;14:353–60.
Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. The Journal of urology 2007;178:1398-403; discussion 1403.
Paulis G, Brancato T, D'Ascenzo R, Giorgio G de, Nupieri P, Orsolini G, et al. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology 2013;1:120–28.
Carthy JM, Sundqvist A, Heldin A, van Dam H, Kletsas D, Heldin C-H, et al. Tamoxifen Inhibits TGF-β-Mediated Activation of Myofibroblasts by Blocking Non-Smad Signaling Through ERK1/2. Journal of cellular physiology 2015;230:3084–92.
Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. British journal of urology 1992;70:648–51.
TELOKEN C, Rhoden EL, GRAZZIOTIN TM, Da ROS CT, SOGARI PR, SOUTO CAV. TAMOXIFEN VERSUS PLACEBO IN THE TREATMENT OF PEYRONIE’S DISEASE. The Journal of urology 1999;162:2003–05.
Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU international 2001;88:63–67.
Ilg MM, Mateus M, Stebbeds WJ, Milenkovic U, Christopher N, Muneer A, et al. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. European urology 2019;75:329–40.
Cocco G, Chu DCC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. European journal of internal medicine 2010;21:503–08.
Dominguez-Malagon HR, Alfeiran-Ruiz A, Chavarria-Xicotencatl P, Duran-Hernandez MS. Clinical and cellular effects of colchicine in fibromatosis. Cancer 1992;69:2478–83.
El-Sakka AI, Bakircioglu ME, Bhatnagar RS, Yen TS, Dahiya R, Lue TF. The effects of colchicine on a Peyronie's-like condition in an animal model. The Journal of urology 1999;161:1980–83.
Akkus E, Breza J, Carrier S, Kadioglu A, Rehman J, Lue TE. Is colchicine effective in Peyronie'sdisease? A pilot study. Urology 1994;44:291–95.
Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. International journal of impotence research 2000;12:169–75.
Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU international 2003;91:522–24.
Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. International journal of impotence research 2004;16:238–43.
Mynderse LA, Monga M. Oral therapy for Peyronie's disease. International journal of impotence research 2002;14:340–44.
Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. European urology 2005;47:530-5; discussion 535-6.
A multicentre doubleblind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease; 1983.
Park TY, Jeong HG, Park JJ, Chae JY, Kim JW, Oh MM, et al. The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor. The World Journal of Men's Health 2016;34:40–46.
Al Attar L, Kilgore W. Rare Incidence of Acute Liver Injury with Potassium Para-Aminobenzoate Introduction. Case reports in gastroenterology 2018;12:230–33.
Trott K-R, Kamprad F. Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiotherapy and Oncology 1999;51:197–203.
Nolan MW, Marolf AJ, Ehrhart EJ, Rao S, Kraft SL, Engel S, et al. Pudendal nerve and internal pudendal artery damage may contribute to radiation-induced erectile dysfunction. International journal of radiation oncology, biology, physics 2015;91:796–806.
Mulhall JP, Hall M, Broderick GA, Incrocci L. Radiation therapy in Peyronie's disease. The journal of sexual medicine 2012;9:1435–41.
Dellis A, Papatsoris A. Stem cell therapy for the treatment of Peyronie's disease. Expert opinion on biological therapy 2017;17:407–13.
Chung E. Stem-cell-based therapy in the field of urology: a review of stem cell basic science, clinical applications and future directions in the treatment of various sexual and urinary conditions. Expert opinion on biological therapy 2015;15:1623–32.
Gokce A, Abd Elmageed ZY, Lasker GF, Bouljihad M, Kim H, Trost LW, et al. Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease. Andrology 2014;2:244–51.
Jiang H, Gao Q, Che X, Zhu L, Zhang Z, Chen Y, et al. Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells. Exp Ther Med 2017;14:5149–56.
Castiglione F, Hedlund P, van der Aa F, Bivalacqua TJ, Rigatti P, van Poppel H, et al. Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease. European urology 2013;63:551–60.
Castiglione F, Hedlund P, Weyne E, Hakim L, Montorsi F, Bivalacqua TJ, et al. Intratunical Injection of Human Adipose Tissue-Derived Stem Cells Restores Collagen III/I Ratio in a Rat Model of Chronic Peyronie's Disease. Sexual medicine 2019;7:94–103.
Hakim L, Fiorenzo S, Hedlund P, Montorsi F, Bivalacqua TJ, Ridder D de, et al. Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis. International journal of impotence research 2020;32:281–88.
Castiglione F, Hedlund P, Weyne E, Hakim L, Montorsi F, Salonia A, et al. Intratunical injection of stromal vascular fraction prevents fibrosis in a rat model of Peyronie's disease. BJU international 2019;124:342–48.
Levy JA, Marchand M, Iorio L, Zribi G, Zahalsky MP. Effects of Stem Cell Treatment in Human Patients With Peyronie Disease. The Journal of the American Osteopathic Association 2015;115:e8-13.
Scott S, Roberts M, Chung E. Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics. Sexual medicine reviews 2019;7:306–12.
Alkandari MH, Touma N, Carrier S. Platelet-Rich Plasma Injections for Erectile Dysfunction and Peyronie's Disease: A Systematic Review of Evidence. Sexual medicine reviews 2022;10:341–52.
Reddy AG, Dick BP, Natale C, Akula KP, Yousif A, Hellstrom WJ. Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now? Sexual medicine reviews 2021;9:320–30.
Russo GI, Cacciamani G, Cocci A, Kessler TM, Morgia G, Serefoglu EC, et al. Comparative Effectiveness of Intralesional Therapy for Peyronie's Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. The journal of sexual medicine 2019;16:289–99.
Chung E, Gillman M, Tuckey J, La Bianca S, Love C. A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association. BJU international 2020;126 Suppl 1:12–17.
Views:
481
Downloads:
135
Copyright (c) 2023 Georgi Tosev, Evgeniya Vladeva, Ivaylo Dimov
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
